TRIAL NUMBER | STATUS | PATIENT | CONDITION | DRUG | DELIVERY ROUTE | END POINT | |
NCT 00520780 (FAIR-HF) | COMPLETED | 456 | HF, ID, IDA | FCM | i.v. | SELF-REPORTED PATIENT GLOBAL ASSESSMENT (PGA) AND NYHA FUNCTIONAL STATUS 24 WEEKS AFTER INITIATION OF THERAPY | |
NCT03036462 | RECRUITING | 1200 | HF | FCM | i.v. | RECURRENT HF HOSPITALIZATIONS AND CARDIOVASCULAR DEATH (NUMBER OF EVENTS) | |
NCT02937454 (AFFIRM-HF STUDY) | COMPLETED | 1132 | HF | FCM | i.v. | HF HOSPITALIZATIONS AND CV DEATH. | |
NCT02642562 (IRONMAN) | COMPLETED | 1160 | HF, LVSD | FERRIC DERISOMALTOSE | i.v. | CV MORTALITY OR HOSPEDALIZATION FOR WORSENING HF | |
NCT03344523 | UNKNOWN | 600 | HF | IRON PROTEIN SUCCINYLATE | oral | PERFORMANCE OF 6 MINUTE WALK DISTANCE | |
NCT05702970 | NOT YET RECRUITING | 258 | HF | SUCROSOMIAL IRON, VIT D FCM | oral, i.v. | PERFORMANCE OF THE SIX-MINUTE WALKING TEST, | |
NCT01453608 (CONFIRM-HF) | COMPLETED | 304 | HF | FCM | i.v. | EXERCISE CAPACITY (CHANGE IN SIX MINUTE WALK TEST FROM BASELINE TO WEEK 24) | |
NCT05691257 | NOT YET RECRUITING | 300 | HF, ANEMIA IN CHRONIC KIDNEY DISEASE | RECOMBINANT HUMAN EYTHROPOIETIN, FERROUS SUCCINATE, POLYSACCHARIDE IRON COMPLEX, IRON SUCROSE | oral, i.v. | CHANGE IN HEMOGLOBIN FROM BASELINE | |
NCT05793996 | RECRUITING | 100 | HF | FCM | i.v. | QUALITY OF LIFE INDICATORS | |
NCT05759078 | RECRUITING | 2000 | MI | FCM | i.v. | THE RISK OF CV DEATH, HF EVENTS | |
NCT04786769 | NOT YET RECRUITING | 2500 | AS | FCM | i.v. | HOSPITAL ADMISSION OR CV DEATH IN TAVI OR SAVR PATIENTS | |
NCT05697211 | RECRUITING | 50 | HF | FERRIC MALTOL | oral | THE SAFETY, TOLERABILITY AND EFFICACY OF ORAL FERRIC MALTOL | |
NCT04945707 (IRONMET-HFpEF) | RECRUITING | 66 | HF | FERRIC DERISOMALTOSE | i.v. | CHANGE IN PEAK OXYGEN UPTAKE FROM BASELINE TO WEEK 12 | |
NCT03380520 | COMPLETED | 75 | HF | FCM | i.v. | CHANGE IN LVEF FROM BASELINE | |
NCT03398681 | COMPLETED | 53 | HF | FCM | i.v. | CHANGES IN MYOCARDIAL IRON CONTENT |